Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study was to assess the effect of a single dose of gefapixant 100 mg on cough reflex sensitivity to various challenge agents (capsaicin, citric acid, adenosine triphosphate [ATP], and distilled water) in healthy and chronic cough participants.


Clinical Trial Description

The study had a Screening period to determine participant inclusion, two Baseline Visits, and two treatment periods with a minimum 48-hour washout between the treatment periods. At Baseline and during each treatment period, cough sensitivity was measured by standard clinical methodology incorporating four cough challenges. Daytime cough monitoring was performed at Baseline and during each of the two treatment periods (chronic cough participants only). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02476890
Study type Interventional
Source Afferent Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date October 28, 2015
Completion date October 20, 2016

See also
  Status Clinical Trial Phase
Completed NCT03282591 - Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Phase 2
Completed NCT03407014 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Recruiting NCT05599191 - A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3
Recruiting NCT03662269 - Indomethacin for Refractory Chronic Cough Phase 3
Recruiting NCT05962151 - Refractory Chronic Cough Improvement Via NAL ER (RIVER) Phase 2
Recruiting NCT05110144 - Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Phase 2
Active, not recruiting NCT04882943 - COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Enrolling by invitation NCT05733533 - A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough Phase 2
Completed NCT02349425 - A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Phase 2
Recruiting NCT05600777 - A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2) Phase 3
Completed NCT05628740 - Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 Phase 1
Not yet recruiting NCT06213363 - A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough Phase 1/Phase 2
Completed NCT02412020 - Treatment of Refractory Chronic Cough With PA101 Phase 2
Completed NCT04678206 - Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 2
Completed NCT02612623 - An 8-Week Refractory Chronic Cough Study (MK-7264-021) Phase 2
Completed NCT02612610 - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Phase 2
Completed NCT02397460 - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Phase 2
Not yet recruiting NCT05265871 - ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough